Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis?

References

• Burr DB. Targeted and nontargeted remodeling. Bone 2002;30:2-4
   PubMed Web of Science ®Google Scholar
• Heaney RP. Remodeling and skeletal fragility. Osteoporos Int 2003;14(Suppl 5):S12-S15
   PubMedGoogle Scholar
• McClung MR, San MJ, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8
   PubMed Web of Science ®Google Scholar
• Johnell O, Scheele W, Lu Y, et al. Additive effects of raloxifene and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985-92
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003;289:2525-33
   PubMed Web of Science ®Google Scholar
• Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. [See comments.] J Clin Endocrinol Metab 2001;86:1890-7
   PubMed Web of Science ®Google Scholar
• Meschia M, Brincat M, Barbacini P, et al. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 1993;53:17-20
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Wyland JJ, Lee H, et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2010;95:1838-45
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-26
   PubMed Web of Science ®Google Scholar
• Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005;20:1905-11
   PubMed Web of Science ®Google Scholar
• Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5
   PubMed Web of Science ®Google Scholar
• Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001;16:925-31
   PubMed Web of Science ®Google Scholar
• Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011;26:503-11
   PubMed Web of Science ®Google Scholar
• Ettinger B, San MJ, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-51
   PubMed Web of Science ®Google Scholar
• Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008;93:3785-93
   PubMed Web of Science ®Google Scholar
• Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 2009;94:3772-80
   PubMed Web of Science ®Google Scholar
• Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-65
   PubMed Web of Science ®Google Scholar
• Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-34
   PubMed Web of Science ®Google Scholar
• Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004;15:992-7
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Wyland JJ, Leder BZ, et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 2009;94:2495-501
   PubMed Web of Science ®Google Scholar
• Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353:566-75
   PubMed Web of Science ®Google Scholar
• Cosman F, Nieves JW, Zion M, et al. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res 2009;24:1110-15
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
   PubMed Web of Science ®Google Scholar
• Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010;25:937-47
   PubMed Web of Science ®Google Scholar
• Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26
   PubMed Web of Science ®Google Scholar